tradingkey.logo
tradingkey.logo

Stevanato Group SpA

STVN
13.600USD
-0.020-0.15%
Market hours ETQuotes delayed by 15 min
4.01BMarket Cap
31.18P/E TTM

Stevanato Group SpA

13.600
-0.020-0.15%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Stevanato Group SpA

Currency: USD Updated: 2026-03-27

Key Insights

Stevanato Group SpA's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 57 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.89.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Stevanato Group SpA's Score

Industry at a Glance

Industry Ranking
57 / 208
Overall Ranking
157 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Stevanato Group SpA Highlights

StrengthsRisks
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 12.27%.
Undervalued
The company’s latest PE is 30.79, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 54.61M shares, decreasing 21.22% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 957.00 shares of this stock.

Analyst Rating

Based on 11 analysts
Buy
Current Rating
25.893
Target Price
+90.11%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Stevanato Group SpA is 8.09, ranking 47 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 297.84M, representing a year-over-year decrease of 2.85%, while its net profit experienced a year-over-year decrease of 8.76%.

Score

Industry at a Glance

Previous score
8.09
Change
0

Financials

6.58

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

9.09

Operational Efficiency

9.03

Growth Potential

10.00

Shareholder Returns

5.73

Stevanato Group SpA's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Stevanato Group SpA is 4.10, ranking 195 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 30.79, which is 126.30% below the recent high of 69.67 and 0.00% above the recent low of 30.79.

Score

Industry at a Glance

Previous score
4.10
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 57/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Stevanato Group SpA is 8.36, ranking 45 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 28.00, with a high of 37.00 and a low of 23.00.

Score

Industry at a Glance

Previous score
8.36
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts
Buy
Current Rating
25.893
Target Price
+90.11%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

115
Total
6
Median
9
Average
Company name
Ratings
Analysts
Stevanato Group SpA
STVN
11
Medtronic PLC
MDT
34
Stryker Corp
SYK
33
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
31
1
2
3
...
23

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Stevanato Group SpA is 6.44, ranking 130 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 16.38 and the support level at 11.68, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.18
Change
0.26

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.216
Sell
RSI(14)
33.428
Neutral
STOCH(KDJ)(9,3,3)
11.818
Oversold
ATR(14)
0.680
Low Volatility
CCI(14)
-221.436
Oversold
Williams %R
82.210
Oversold
TRIX(12,20)
-0.423
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
14.074
Sell
MA10
14.612
Sell
MA20
15.012
Sell
MA50
15.878
Sell
MA100
18.911
Sell
MA200
21.826
Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Stevanato Group SpA is 10.00, ranking 1 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 109.86%, representing a quarter-over-quarter decrease of 2.14%. The largest institutional shareholder is Ron Baron, holding a total of 2.00M shares, representing 4.03% of shares outstanding, with 8.06% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Conestoga Capital Advisors, LLC
8.09M
-0.37%
Neuberger Berman, LLC
4.96M
+1.78%
T. Rowe Price Investment Management, Inc.
3.55M
-4.83%
TimesSquare Capital Management, LLC
3.27M
-1.74%
Thrivent Asset Management, LLC
2.37M
+7.07%
Artisan Partners Limited Partnership
2.61M
-4.41%
Baron Capital Management, Inc.
Star Investors
1.97M
+4.54%
Jennison Associates LLC
1.56M
+43.65%
Ranger Investment Management, L.P.
1.28M
-2.94%
Pembroke Management Ltd.
1.28M
+11.92%
1
2

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Stevanato Group SpA is 5.24, ranking 86 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
5.24
Change
0
Beta vs S&P 500 index
0.64
VaR
--
240-Day Maximum Drawdown
+51.95%
240-Day Volatility
+60.50%

Return

Best Daily Return
60 days
+18.81%
120 days
+18.81%
5 years
--
Worst Daily Return
60 days
-9.86%
120 days
-9.86%
5 years
--
Sharpe Ratio
60 days
-2.43
120 days
-2.28
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+51.95%
3 years
+62.16%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.75
3 years
-0.28
5 years
--
Skewness
240 days
+0.82
3 years
+0.09
5 years
--

Volatility

Realised Volatility
240 days
+60.50%
5 years
--
Standardised True Range
240 days
+8.44%
5 years
--
Downside Risk-Adjusted Return
120 days
-404.18%
240 days
-404.18%
Maximum Daily Upside Volatility
60 days
+48.47%
Maximum Daily Downside Volatility
60 days
+44.83%

Liquidity

Average Turnover Rate
60 days
+0.12%
120 days
+0.12%
5 years
--
Turnover Deviation
20 days
-17.17%
60 days
-19.88%
120 days
-21.32%

Peer Comparison

Healthcare Equipment & Supplies
Stevanato Group SpA
Stevanato Group SpA
STVN
7.12 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI